Status of work in February
AOTMiT begins work on the Ministry of Health’s orders in February:
- Mibrex (Rivaroxabanum) for the prevention of thrombotic events in adults with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischemic events
- Qalsody (Tofersen) in the treatment of amyotrophic lateral sclerosis
The listed orders are available on the AOTMiT Public Information Bulletin.